

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- 1. Ifinatamab deruxtecan (I-DXd) targets which of the following proteins?**
  - a. HER2
  - b. HER3
  - c. TROP2
  - d. B7-H3**
- 2. What is the overall response rate in the small cell lung cancer (SCLC) cohort of the Phase I/II DS7300-A-J101 trial evaluating the novel antibody-drug conjugate I-DXd?**
  - a. 9%
  - b. 18%
  - c. 52%**
  - d. 91%
- 3. Which of the following treatments is being compared to treatment of physician's choice for relapsed SCLC in the Phase III IDEate-Lung02 trial?**
  - a. Tumor treating fields (TTFields)
  - b. Tarlatamab
  - c. I-DXd**
  - d. None of the above
- 4. Which of the following adverse events was observed as being the most common all-grade toxicity associated with TTFields in the Phase III LUNAR trial?**
  - a. Edema
  - b. Alopecia
  - c. Pneumonia
  - d. Dermatitis**
- 5. The Phase III METIS trial evaluating TTFields for patients with metastatic non-small cell lung cancer and brain metastases demonstrated which of the following outcomes in terms of median time to intracranial progression?**
  - a. It was shorter with TTFields compared to control
  - b. It almost doubled with TTFields compared to control**
  - c. There was no difference between TTFields and control